Laurus Labs

₹776 17.9 | 2.4%

WEBSITE BSE:540222 NSE : LAURUSLABS 04 Jul, 15:57

Market Cap ₹41876 Cr.

Stock P/E 118.2

P/B 9.4

Current Price ₹776

Book Value ₹ 82.4

Face Value 2

52W High ₹777.9

Dividend Yield 0.15%

52W Low ₹ 390.3

Edit Ratio

Laurus Labs Research see more...

Overview Inc. Year: 2005Industry: Pharmaceuticals & Drugs

Laurus Labs Ltd is an India-based producer of active pharmaceutical ingredients (APIs) for anti-etrovirals (ARVs), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology. The Company develops and manufactures oral stable formulations, gives contract research and manufacturing services (CRAMS) and contract development and manufacturing company (CDMO) to the global pharmaceutical companies. The Company also produces special substances for nutraceuticals, dietary supplements, and cosmeceuticals. Its business gadgets includes Generics APIs, Generics Finished Dosage Forms (FDFs) and Synthesis/Ingredients. The Generics APIs enterprise accommodates the development, manufacture and sale of APIs and advanced intermediates inside the ARV, Hepatitis C, oncology, cardiovascular, anti-diabetic, anti-asthmatic, gastroenterology and ophthalmic therapeutic regions. The Generics FDFs is engaged in growing and manufacturing oral stable formulations.

Laurus Labs Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Laurus Labs Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Laurus Labs Profit & Loss

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Net Sales	1327	1778	1905	2056	2292	2832	4814	4936	6041	5041	5554
Other Income	34	4	33	29	16	6	24	15	6	26	75
Total Income	1361	1782	1938	2085	2308	2838	4837	4951	6047	5067	5629
Total Expenditure	1131	1415	1497	1643	1936	2267	3263	3513	4448	4263	4499
Operating Profit	229	367	441	443	372	570	1574	1438	1598	804	1130
Interest	101	111	100	80	88	90	68	102	165	183	216
Depreciation	62	86	106	125	164	187	205	251	324	385	430
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	67	169	235	237	120	294	1301	1084	1109	236	484
Provision for Tax	-2	35	44	70	26	38	317	251	312	68	130
Profit After Tax	68	134	191	168	94	255	984	832	797	168	354
Adjustments	0	-0	-1	0	0	0	-0	-5	-12	-11	4
Profit After Adjustments	68	134	190	168	94	255	984	828	785	158	358
Adjusted Earnings Per Share	2.2	4.2	3.6	3.2	1.8	4.8	18.3	15.4	14.6	2.9	6.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	10%	4%	14%	15%
Operating Profit CAGR	41%	-8%	15%	17%
PAT CAGR	111%	-25%	7%	18%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	71%	18%	48%	NA%
ROE Average	8%	11%	21%	17%
ROCE Average	10%	13%	21%	17%

Laurus Labs Balance Sheet

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Shareholder's Funds	722	857	1330	1483	1558	1770	2598	3351	4038	4111	4473
Minority's Interest	0	0	0	0	0	0	3	8	11	5	130
Borrowings	304	460	125	142	259	165	429	596	761	798	646
Other Non-Current Liabilities	60	-32	8	33	37	49	264	332	418	361	548
Total Current Liabilities	802	884	1121	1307	1424	1692	2457	2681	2432	3112	3540
Total Liabilities	1888	2169	2584	2964	3278	3676	5751	6968	7660	8387	9336
Fixed Assets	801	1021	1230	1481	1629	1726	2171	2652	3409	3890	4123
Other Non-Current Assets	223	145	214	235	186	138	505	971	790	662	880
Total Current Assets	862	1003	1140	1248	1463	1812	3075	3345	3462	3835	4332
Total Assets	1888	2169	2584	2964	3278	3676	5751	6968	7660	8387	9336

Laurus Labs Cash Flow

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Opening Cash & Cash Equivalents	15	40	13	2	3	3	2	48	75	46	139
Cash Flow from Operating Activities	-65	182	332	342	298	347	733	911	994	666	602
Cash Flow from Investing Activities	-397	-312	-289	-384	-253	-221	-941	-914	-996	-822	-682
Cash Flow from Financing Activities	486	103	-54	42	-45	-128	255	30	-27	250	39
Net Cash Inflow / Outflow	24	-27	-10	1	0	-1	47	27	-29	93	-41
Closing Cash & Cash Equivalent	40	13	2	3	3	2	48	75	46	139	100

Laurus Labs Ratios

#	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Earnings Per Share (Rs)	2.2	4.24	3.56	3.16	1.76	4.78	18.33	15.4	14.56	2.93	6.64
CEPS(Rs)	4.18	6.99	5.62	5.53	4.85	8.28	22.16	20.17	20.81	10.26	14.55
DPS(Rs)	0	0.4	0.3	0.3	0.3	0.5	2	2	2	0.8	1.2
Book NAV/Share(Rs)	20.98	24.96	25.05	27.86	29.18	33.02	48.32	62.19	74.73	75.88	82.46
Core EBITDA Margin(%)	14.58	20	21.1	19.98	15.53	19.94	32.22	28.82	26.36	15.42	19
EBIT Margin(%)	12.53	15.47	17.35	15.32	9.07	13.53	28.45	24.03	21.09	8.32	12.61
Pre Tax Margin(%)	4.98	9.33	12.18	11.47	5.22	10.37	27.03	21.96	18.36	4.69	8.72
PAT Margin (%)	5.09	7.41	9.91	8.1	4.09	9.01	20.44	16.87	13.19	3.34	6.38
Cash Profit Margin (%)	9.69	12.18	15.39	14.16	11.26	15.63	24.7	21.96	18.55	10.97	14.13
ROA(%)	4.31	6.61	8.05	6.04	3	7.34	20.87	13.09	10.89	2.1	4
ROE(%)	14.47	18.65	18.12	11.97	6.19	15.39	45.15	28.05	21.63	4.15	8.3
ROCE(%)	13.74	16.35	16.52	13.68	8.22	14.14	39.82	25.97	22.97	6.64	10.16
Receivable days	65.47	73.56	95.66	100.4	101.97	96.76	79.52	98.37	88.66	117.42	120.6
Inventory Days	109.61	97	94.12	96.48	100.87	102.29	94.05	123.34	104.09	127.81	124.27
Payable days	101.84	87.3	94.21	99.44	119.3	145.69	155.37	175.76	106.1	135.42	153.14
PER(x)	0	0	28.91	31.83	45.38	13.51	19.75	38.31	20.12	133.9	92.37
Price/Book(x)	0	0	4.11	3.61	2.74	1.95	7.49	9.49	3.92	5.16	7.44
Dividend Yield(%)	0	0	0.29	0.3	0.38	0.77	0.55	0.34	0.68	0.2	0.2
EV/Net Sales(x)	0.64	0.61	3.3	3.07	2.31	1.59	4.33	6.76	2.93	4.66	6.42
EV/Core EBITDA(x)	3.68	2.95	14.25	14.26	14.21	7.9	13.23	23.2	11.08	29.21	31.54
Net Sales Growth(%)	14.39	34	7.15	7.96	11.47	23.55	69.99	2.54	22.39	-16.55	10.18
EBIT Growth(%)	-6.62	67.08	19.61	-5.38	-34.42	84.28	257.33	-13.37	7.41	-67.09	67.03
PAT Growth(%)	-29.93	96.91	42.64	-12.4	-44.06	172.25	285.4	-15.39	-4.3	-78.89	110.7
EPS Growth(%)	-30.27	92.45	-15.95	-11.31	-44.27	171.04	283.84	-15.98	-5.42	-79.91	127.12
Debt/Equity(x)	1.14	1.2	0.64	0.66	0.67	0.6	0.56	0.52	0.49	0.61	0.61
Current Ratio(x)	1.07	1.13	1.02	0.95	1.03	1.07	1.25	1.25	1.42	1.23	1.22
Quick Ratio(x)	0.48	0.58	0.56	0.51	0.55	0.54	0.61	0.59	0.73	0.64	0.68
Interest Cover(x)	1.66	2.52	3.35	3.98	2.36	4.28	20.09	11.59	7.71	2.29	3.24
Total Debt/Mcap(x)	0	0	0.15	0.18	0.24	0.31	0.07	0.05	0.12	0.12	0.08

Laurus Labs Shareholding Pattern

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	27.2	27.2	27.2	27.2	27.19	27.19	27.18	27.18	27.62	27.62
FII	21.89	22.4	22.52	24.03	25.39	25.97	25.67	26.08	25.56	25.52
DII	9.53	9.75	10.35	11.01	11.13	11.77	13.56	13.05	12.74	11.77
Public	41.39	40.64	39.93	37.76	36.29	35.07	33.59	33.69	34.08	35.09
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	14.65	14.65	14.65	14.65	14.65	14.65	14.65	14.65	14.9	14.9
FII	11.79	12.07	12.13	12.94	13.68	14	13.84	14.06	13.78	13.76
DII	5.13	5.25	5.57	5.93	6	6.34	7.31	7.03	6.87	6.35
Public	22.29	21.89	21.51	20.34	19.56	18.9	18.11	18.17	18.38	18.92
Others	0	0	0	0	0	0	0	0	0	0
Total	53.87	53.87	53.87	53.87	53.9	53.9	53.92	53.92	53.93	53.93

Pros

Company has reduced debt.

Cons

Promoter holding is low: 27.62%.
Company has a low return on equity of 11% over the last 3 years.
Debtor days have increased from 135.42 to 153.14days.
Stock is trading at 9.4 times its book value.
The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Laurus Labs News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Laurus Labs

Add Watchlist

Laurus Labs Research see more...

Overview Inc. Year: 2005Industry: Pharmaceuticals & Drugs

Laurus Labs Share Price

Alert Data

Quarterly Price

Peer Comparison

Laurus Labs Quarterly Results

Laurus Labs Profit & Loss

Growth Rates

Laurus Labs Balance Sheet

Laurus Labs Cash Flow

Laurus Labs Ratios

Laurus Labs Shareholding Pattern

Laurus Labs News

IPO

Sharescart: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!

Enter Your Complaint